New in @IJROBP by #proton fellow Dr Irini Youssef & @imrtlee: There was a difference in biologic dose in high/low-uptake regions on 3-mo post-IMPT. However, this did not translate to PET uptake in the CTVp at 3 & 6-mo follow-up between IMPT & IMRT. #hncsm
https://t.co/vTQGpEScIg
New from former @MSKCancerCenter#proton Dr @AnnaLeeMDMPH with @imrtlee: Compared with previous reports of photon-based #reirradiation, pts are living longer with aggressive proton-ReRT; however, surviving pts remain at risk of early & late complications.
https://t.co/6qP1fE32Kc
Our new study on oropharyngeal cancer (OPC): proton therapy with IMPT for localized OPC is associated with fewer acute toxicities compared to standard of care IMRT, without compromising OS, PFS or LRR.
https://t.co/hkmoFM4vyo
@nataliezumab Caggio and raphex questions! RadoncQ has amazing explanations (more detailed than the 1-2 sentences raphex provides) so i used their explanations as a more detailed resource for sure.
I absolutely love this authentic piece by @ramsedhom.
"Yet, the metrics of success—esp at the trainee & early-career level—are often arbitrary, involve self-promotion, and are devoid of meaning, societal or community advancement."
#MedEd#MedTwitter
https://t.co/Teu5Snqxf6